The approved schedule begins at 0.25 mg once weekly for four weeks, an amount the prescribing information describes as being for treatment initiation rather than glycemic control. It then moves to 0.5 mg weekly for at least four weeks, with later increases available. Escalation exists to limit gastrointestinal effects, and its pace is a prescriber decision.
What the approved schedule looks like
Semaglutide for type 2 diabetes has a published titration path in its labeling, and it is unusually explicit about the purpose of each step. The first four weeks are a tolerance ramp. The label states outright that the opening amount is not intended to control blood sugar, which surprises people who expect an immediate effect and conclude the drug is not working.
| Step | Minimum time before an increase | What the label says it is for |
|---|---|---|
| 0.25 mg weekly | 4 weeks | Treatment initiation, not glycemic control |
| 0.5 mg weekly | At least 4 weeks | First maintenance option |
| 1 mg weekly | At least 4 weeks | Increase if further glycemic control is needed |
| 2 mg weekly | Maximum labeled amount | Further increase where needed |
Two points about that table matter more than the numbers in it. The intervals are minimums, not deadlines, and no step is obligatory. A patient who reaches an acceptable result at an earlier step has no automatic reason to keep climbing.
Versions of this schedule turn up on a lot of provider pages, which is worth knowing before treating any single one as authoritative. Ro and Hims and Hers restate the labeled steps, HealthRX publishes its own patient explainer on Ozempic, and manufacturer channels such as NovoCare Pharmacy present the branded pen. A summary like that sets rough expectations, but the pace a given patient actually follows is decided by the prescriber watching how each step is tolerated, not by whichever table was read first.
Why titration exists at all
GLP-1 receptor agonists slow gastric emptying and act on receptors in the gut and brain that influence nausea and satiety. The same mechanism that produces the therapeutic effect produces the unwanted one, which is why the two scale together rather than separating cleanly.
Dose-ranging work with semaglutide showed this directly: gastrointestinal adverse events rose with the amount given, and slower escalation improved how many people stayed on treatment. The phase 3 program for type 2 diabetes reported the same pattern, with nausea, vomiting, and diarrhea concentrated in the weeks around an increase and easing at a steady amount.
Adaptation is real but takes time. That is the entire argument for a ramp rather than starting at a maintenance amount.
What a prescriber weighs when a step is not tolerated
The options are not binary. Holding at the current amount for longer than the minimum interval is standard and does not represent failure. Stepping back to the previous amount and re-attempting later is also standard. Stopping is the last option rather than the first, because the alternative to a slower ramp is often no treatment at all.
Several other factors enter the decision. Whether the person is also taking insulin or a sulfonylurea, since combination therapy shifts the hypoglycemia risk and may call for adjusting the other agent rather than the semaglutide. Whether fluid intake has fallen enough to threaten kidney function. Whether symptoms are the expected pattern or something that looks different, such as pain radiating to the back.
None of that is a calculation a patient can run alone, which is why symptom reporting between visits matters more than it appears to.
Tolerability, not efficacy, is what usually ends treatment early
Real-world follow-up of semaglutide users shows meaningful discontinuation within the first year, and the timing points at the escalation window rather than at a judgment about results. People who leave in the first two months rarely leave because the drug did nothing. They leave because a week felt intolerable and no one had told them slowing down was allowed.
That framing changes behavior. Someone who believes the schedule is fixed treats a bad week as a reason to quit. Someone who knows a hold is available treats it as a reason to call.
What to establish before the first injection
The practical questions are about the process rather than the pharmacology. Who authorizes a hold, and how quickly. Whether escalation happens automatically on a calendar or only after a check-in. What the contact route is when symptoms appear on a weekend. Whether the same clinician follows the case or each contact starts over.
Answers vary a great deal between access routes. Endocrinology and primary care practices, manufacturer channels such as NovoCare Pharmacy and LillyDirect, and direct-to-consumer telehealth companies including Ro, Hims & Hers, LifeMD, and formblends.com all handle between-visit escalation questions on different timelines and at different price points. It is a fair thing to ask about before paying rather than during a difficult week.
The cost angle is connected to this. A program that charges per consultation creates a quiet incentive not to call, which is the opposite of what a titration period needs.
Compounded semaglutide is a separate question
The schedule above describes an FDA-approved product with a fixed concentration and a labeled device. Compounded semaglutide is not FDA-approved, and its concentration is set by the compounding pharmacy rather than by a label the agency has reviewed.
Because of that, the numbers in the approved labeling do not transfer to a compounded vial, and no equivalent published schedule exists for one. Any titration plan for a compounded preparation comes from the prescriber who wrote it and the pharmacy that made it, and it is not something to reconstruct from a branded label or from what someone else was told.
Where escalation and expectations diverge
Ozempic is approved for type 2 diabetes in adults and to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Wegovy is the semaglutide product approved for chronic weight management, and it has a longer titration path to a higher maintenance amount. People who read weight-management timelines and apply them to a diabetes prescription end up expecting steps that are not in their own labeling.
Both products carry a boxed warning about thyroid C-cell tumors observed in rodents, and both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. That is a screening question before the first dose, not something raised mid-escalation.
Frequently asked questions
Is a slower ramp less effective?
Not in any way that shows up over months. Reaching a workable amount two months later than the minimum schedule allows costs little, while stopping entirely because of an intolerable week costs everything. Staying on treatment is the variable that drives the result.
Does everyone need to reach the maximum labeled amount?
No. The higher steps exist for people who need additional glycemic control, not as a target in themselves. A patient meeting their goal at an earlier step has no built-in reason to keep increasing, and that decision sits with the prescriber.
How long do symptoms after an increase usually last?
They are typically worst in the days immediately after a step and settle over the following weeks at a steady amount. Symptoms that keep worsening, or that persist without any improvement, are worth reporting rather than waiting out.
Can a step be repeated instead of advanced?
Yes, and it is a routine adjustment rather than an exception. Extending time at the current amount, or returning to the previous one before trying again, are both recognized responses to poor tolerability and are decided by the prescriber.
Why is the opening amount the same for everyone?
Because it is a tolerance ramp rather than a therapeutic amount, and tolerance does not track body size in a predictable way. The labeled starting step is not weight-based for that reason.
